E Therapeutics (ETX)
ETX Share PerformanceMore
|52 week high||29.9000 02/11/15|
|52 week low||8.9000 20/09/16|
|52 week change||-18.0000 (-66.06%)|
|4 week volume||2,631,941 26/09/16|
Latest News« previous» nextMore
06/10/2016 - 10:25 StockMarketWire
Prof Trevor Jones, Non Executive Director, bought 41,204 shares in the company on the 5th October 2016 at a price of 11.33p...
06/10/2016 - 10:12 RNS
RNS Number: 8817L e-Therapeutics plc 06 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Directors' Dealings and Issue of Equity Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that o n 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,20...
03/10/2016 - 14:03 RNS
RNS Number: 5273L e-Therapeutics plc 03 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Further re: Directors' Shareholdings 3 October 2016, Oxford and Newcastle, UK: Further to e-Therapeutics' announcement on 21 September 2016, the Company announces the following additional detail on the increase to Sean Nicolson's shareholding in the Com...
21/09/2016 - 16:06 RNS
RNS Number: 4832K e-Therapeutics plc 21 September 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Issue of Equityand Directors' Shareholdings 21 September 2016, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery company, announces the issue, pursuant to the Company's offer for the issued and to be issued share capital of Se...
20/09/2016 - 07:27 StockMarketWire
e-Therapeutics posts an operating loss of 9.7m for the six months to the end of July (HY15: loss of 5.9m), including 2.1m good...
20/09/2016 - 07:00 RNS
RNS Number: 2536K e-Therapeutics plc 20 September 2016 e-Therapeutics ('e-Therapeutics' or the 'Company') Re-focused, science based and commercially driven with 19.9m of cash 20 September 2016: e-Therapeutics plc (AIM: ETX), the drug discovery company, announces its half year results for the six months ended 31 July 2016. Highlights Cash and deposits of 19.9m (...
14/09/2016 - 12:08 RNS
RNS Number: 8368J e-Therapeutics plc 14 September 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Management Update Oxford, UK, 14 September 2016 - e-Therapeutics plc ( AIM :ETX )announces that following its full year results statement on 22 March 2016 which highlighted the Company's strategic refocus on its discovery platform, Steve Self will stan...
09/09/2016 - 09:46 StockMarketWire
e-Therapeutics, the drug discovery company, will announce its half year results for the six months ended 31 July on 20 Sep...
|Dividend yield||0 %|
Equity Research (ETX)
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19....
e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and...
e-Therapeutics’ (ETX) share price fell c 30% on news that the ETS6103 Phase IIb trial as a second-line therapy for major depressive disorder (MDD) failed to meet its primary efficacy endpoint....
- 1 of 3
Latest discussion posts More
“RNS available at company's website. although seems to be missing in III ...”▼
“RNS out today afternoon. Good operational progress. Not sure if that warrants a steep rise in SP as seen over the last few days, including a further 15% today. But I ...”▼
“Clearly somebody knows something we don't. Would that be called insider trading I wonder.”▼
Codes & Symbols
|Symbols||ETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX|